Citable stop point · derived public projection · v0.1
China non-squamous NSCLC evidence pathway
The assembled public evidence can rank surgery, drug therapy, transplantation, and ECMO for an individual with non-squamous NSCLC in China.
China non-squamous NSCLC; clinical stage, resectability, EGFR status, prior treatment, and fitness determine which evidence is relevant. The defined drug-trial cohort is EGFR-mutated, locally advanced or metastatic disease after EGFR-TKI progression.
Knowledge cutoff 2026-09-28; public research preview v0.1; clinical interpretation review pending.
PUBLIC RESEARCH PREVIEW · PERSONAL ESTIMATE NOT ESTABLISHED
Separate stage-specific surgical guidance and an operated cohort, a China-approved regimen and randomized trial result for its defined population, and an ECMO utilization count.
A patient-specific success probability or cross-modality ranking. ECMO is life support, not tumor therapy; transplantation is exceptional and not established for the indexed advanced post-TKI cohort. No hospital-specific outcome dataset has been acquired for this case.
For the public research gap, request a documented written response on availability and permitted aggregate analysis of a defined hospital cohort; this would not by itself yield an individual forecast.
A citation is incomplete if “Does not support” is omitted. Derived from the published research preview. No hospital data were purchased or analyzed and no clinical interpretation review is claimed.